NCT02902939View on ClinicalTrials.gov

Myeloid-Derived Supressor Cells in Cardiac Surgery Patients

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

July 19, 2018

Study Completion Date

July 19, 2018

Conditions
Insufficiency; Cardiac, Complicating SurgerySystemic Inflammatory Response Syndrome
Interventions
DEVICE

minimal extracorporeal circulation (MEC)

We should use the modification of extracorporeal circulation to reduce the systemic inflammatory response due to excessive haemodilution, allogenic blood transfusion.

PROCEDURE

The cytokines modulations

We should use the modification of cytokines by CytoSorb devices and cytokines removal by PMMA membranes during extracorporeal circulation in patients with risk factors of complications (long duration of extracorporeal circulation, re-do procedures and other)

Trial Locations (1)

650002

Georgy Plotnikov, Kemerovo

All Listed Sponsors
lead

Research Institute for Complex Problems of Cardiovascular Diseases, Russia

OTHER

NCT02902939 - Myeloid-Derived Supressor Cells in Cardiac Surgery Patients | Biotech Hunter | Biotech Hunter